Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction

Aimo, Alberto; Gaggin, Hanna K.; Barison, Andrea; Emdin, Michele; Januzzi, James L.

doi:10.1016/j.jchf.2019.06.004

Cited by 122 publications

(130 citation statements)

References 49 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…Our data confirm the association of baseline patient characteristics related to LVEF recovery 1,5,6,9–11 , and demonstrate two novel findings in patients with pre‐existing HFrecEF: (i) evidence of additional LVEF improvement at a median 2 years following initial diagnosis and (ii) lower baseline and stable serum hs‐TnT levels in contrast to increasing levels in those with persistent HFrEF. Taken together, these findings support the notion that significant improvement in LVEF may occur after 2 years and associate with lower and stable serum levels of cardiac damage.…”

Section: Discussionsupporting

confidence: 81%

“…Several correlates for LVRR have been reported in most studies, including younger age, female sex, non-ischaemic aetiology, shorter duration of HF, higher baseline LV volume, and use of beta blockers. 1,6,7 Other factors reported to associate with LVRR, such as the presence of the minor allele of re777652, a hypocretin receptor-2. 17 Recently, hs-TnT has been reported to associate with outcomes in HF with a meta-analysis of studies suggesting a level < 18 ng/L to predict lower risk of death and hospitalization, but this level was not tested for prediction of reverse remodelling.…”

Section: Predictors Of Late Left Ventricular Reverse Remodellingmentioning

confidence: 99%

“…18 Others have suggested superior predictive strength for LV recovery of circulating ST2 level, where a score has been developed and validated. 1,9,19 However, these results were derived from data at initial diagnosis (disease duration < 1 year) and its correlation with LVRR. In our cohort, the median time from diagnosis of HF to study baseline was 4 years.…”

Section: Predictors Of Late Left Ventricular Reverse Remodellingmentioning

confidence: 99%

“…Treatment of patients with left ventricular (LV) systolic dysfunction using evidence-based medical therapy is associated with improved symptoms and reduced morbidity and mortality. [1][2][3][4][5] Previous reports suggest that patients may demonstrate significant improvement in LV ejection fraction (EF) with evidence-based medical therapy (i.e. reverse remodelling), also referred to as heart failure with recovered EF (HFrecEF).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Circulating troponin and further left ventricular ejection fraction improvement in patients with previously recovered left ventricular ejection fraction

et al. 2020

View full text Add to dashboard Cite

Aims The aim of this study is to determine factors associated with long-term recovery of left ventricular ejection fraction (LVEF) in patients with heart failure with reduced EF (HFrEF) and if further recovery also occurs in this group. Methods and results Among 621 participants enrolled in the Alberta Heart Failure Etiology and Analysis Team (HEART) Study, 316 with Stage C HF underwent comprehensive imaging and biomarker testing at enrolment and at 1-year follow up. Using pre-enrolment data, HF with recovered EF (HFrecEF) was defined as an absolute improvement ≥5% in LVEF from the prior lowest LVEF value, with a final LVEF value > 35% at or prior to study baseline. Participants with all LVEF > 40% were included for comparison. Hospitalization-free survival to 5 years was performed. The median cohort age was 66 years, and time from diagnosis was 4 years; 82% were male patients. Of the 316 patients, 95 (30%) patients had HFrecEF and 56 (18%) patients pHFrEF. On multivariate analysis, only shorter duration of HF was predictive of HFrecEF status. Over 1 year, LVEF increased in the HFrecEF group 4.0% (0.15-7.90, P = 0.042) as compared with persistent HFrEF, who in turn demonstrated higher baseline serum high sensitivity Troponin-T with further increase at follow up 0.55 (0.33-0.86, P = 0.011). No change in any parameter in the HFpEF/HFmrEF group at follow up was observed. Conclusions Patients with HFrecEF demonstrate evidence of additional late improvement in LVEF and unchanged troponin levels, in contrast to those with persistent HFrEF, where LVEF does not improve and serum troponin rises over time. These data help to inform mechanisms relating to late LV remodelling.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Predictors Of Late Left Ventricular Reverse Remodellingmentioning

confidence: 99%

Section: Predictors Of Late Left Ventricular Reverse Remodellingmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Circulating troponin and further left ventricular ejection fraction improvement in patients with previously recovered left ventricular ejection fraction

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Cardiac remodeling often causes changes in the wall thickness, ventricular volumes and cardiac mass, which further leads to reduced ventricular ejection and imbalances in the neurohumoral system, this, in turn, aggravates ventricular remodeling and ultimately causes noncompensatory heart failure (HF). Cardiac remodeling is a remarkable pathogenic manifestation of many serious cardiovascular diseases that ultimately progress to HF [1][2][3][4][5]. Studies have shown that structural, electrical and energetic remodeling are involved in this progression, among which the former two play a leading role [6].…”

Section: Introductionmentioning

confidence: 99%

The Roles of Noncardiomyocytes in Cardiac Remodeling

Yang

Liu

et al. 2020

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Cardiac remodeling is a common characteristic of almost all forms of heart disease, including cardiac infarction, valvular diseases, hypertension, arrhythmia, dilated cardiomyopathy and other conditions. It is not merely a simple outcome induced by an increase in the workload of cardiomyocytes (CMs). The remodeling process is accompanied by abnormalities of cardiac structure as well as disturbance of cardiac function, and emerging evidence suggests that a wide range of cells in the heart participate in the initiation and development of cardiac remodeling. Other than CMs, there are numerous noncardiomyocytes (non-CMs) that regulate the process of cardiac remodeling, such as cardiac fibroblasts and immune cells (including macrophages, lymphocytes, neutrophils, and mast cells). In this review, we summarize recent knowledge regarding the definition and significant effects of various non-CMs in the pathogenesis of cardiac remodeling, with a particular emphasis on the involved signaling mechanisms. In addition, we discuss the properties of non-CMs, which serve as targets of many cardiovascular drugs that reduce adverse cardiac remodeling.

show abstract

Engineering Injectable Anti‐Inflammatory Hydrogels to Treat Acute Myocardial Infarction

Zhang

Liu

2022

Advanced NanoBiomed Research

View full text Add to dashboard Cite

Acute myocardial infarction (AMI) poses serious threats to human health. Suppressing long-term inflammation is a promising strategy to improve cardiac function following AMI. However, the direct injection of anti-inflammatory drugs after AMI can trigger adverse events due to systemic off-target effects and bioavailability issues. Injectable hydrogels can be used for local transportation of various therapeutic molecules through minimally invasive technology to overcome the side effects of intravenous injection. Herein, the anti-inflammatory mechanisms and applications of injectable hydrogels are reviewed to deliver antiinflammatory drugs, antioxidants, immune-regulation drugs, stem cells and their derived exosomes, and therapeutic gas to reduce the inflammatory response to treat AMI. The outlook on challenges in the design of hydrogels for treating AMI is also presented.

show abstract

Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction

Cited by 122 publications

References 49 publications

Circulating troponin and further left ventricular ejection fraction improvement in patients with previously recovered left ventricular ejection fraction

Circulating troponin and further left ventricular ejection fraction improvement in patients with previously recovered left ventricular ejection fraction

The Roles of Noncardiomyocytes in Cardiac Remodeling

Engineering Injectable Anti‐Inflammatory Hydrogels to Treat Acute Myocardial Infarction

Contact Info

Product

Resources

About